

Nemucore Medical Innovations to Present at the Applied Pharmaceutical Nanotechnology Conference

Nemucore to present on November 4th, 2015 at 9:30 a.m. EDT at The Broad Institute

WORCESTER, Mass. - Oct. 29, 2015 - PRLog -- Nemucore Medical Innovations, Inc. (Nemucore), a privately-held global oncology company dedicated to the development and commercialization of molecularly targeted therapies to treat women's multidrug resistant cancers, announced today that the company will present at The Boston Society's Applied Pharmaceutical Nanotechnology conference being held November 4th, 2015 at The Broad Institute in Cambridge.

Timothy P. Coleman, Chief Executive Officer and President of Nemucore, will present a scientific overview entitled, "Translational Studies of Theranostic Nanoemulsions", at 9:30 a.m. EDT on Wednesday, November 4th, 2015 at the conference's 1st session, "Preclinical Tools - Changing Landscape of the Pharmaceutical Sciences". If you would like more information about the presentation please contact Nicole Stephenson at nstephenson@nemucore.com.

About Nemucore Medical Innovations, Inc.

Nemucore Medical Innovations, Inc. is a privately held biopharmaceutical clinical-stage oncology company developing innovative therapeutics, with a focus on treating multi-drug resistant cancers. Nemucore's most advanced product NMI-900, a "Best-In-Class" therapeutic for the treatment of ovarian cancer, is expected to begin a Phase 2b clinical trial in late 2015. Two additional therapeutics are anticipated to begin clinical trials in 2016 targeting further oncology indications, including breast cancer. For more information visit our website www.Nemucore.com

Forward Looking Statement

This press release makes forward-looking statements regarding future events and our future performance about the Company's strategy, future plans and prospects, including statements regarding the development of the Company's therapeutic programs, the timeline for clinical development and regulatory approval of the Company's compounds, the structure of the Company's planned clinical trials, the Company's rights to develop or commercialize its products, the Company's obligations to make milestone payments and royalties and the ability of the Company to finance contemplated development activities. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "proposed," and other similar expressions generally identify forward-looking statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Forward-looking statements entail various significant risks and uncertainties that could cause our actual results to differ materially from those expressed in such forward- looking statements. Applicable risks and uncertainties include the risks that the preclinical testing of the Company's compounds may not be predictive of the success of later clinical trials, that the Company may be unable to successfully complete the clinical development of its products, that the development of the Company's products may take longer or cost more than planned, and that the Company's products may not receive regulatory approval or become commercially successful products. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We do not intend to update any of the information contained in any forward-looking statement, except as required by law. More information about the risks and uncertainties faced by Nemucore Medical Innovations, Inc. is contained in the company's periodic reports filed with the Securities and Exchange Commission. Nemucore Medical Innovations, Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.